Show simple item record

dc.contributor.authorHolmøy, Trygve
dc.contributor.authorLindstrøm, Jonas Christoffer
dc.contributor.authorEriksen, Erik Fink
dc.contributor.authorSteffensen, Linn Hofsøy
dc.contributor.authorKampman, Margitta Theodora
dc.date.accessioned2018-02-16T12:53:57Z
dc.date.available2018-02-16T12:53:57Z
dc.date.issued2017-04-04
dc.description.abstractBackground: <br> People with multiple sclerosis have high risk of osteoporosis and fractures. A poor vitamin D status is a risk factor for MS, and vitamin D supplementation has been recommended both to prevent MS progression and to maintain bone health. <br> Methods: <br> We assessed the effect of 20,000 IU vitamin D3 weekly compared to placebo on biochemical markers of bone metabolism in 68 persons with relapsing remitting multiple sclerosis. <br> Results: <br> Serum levels of 25-hydroxyvitamin D more than doubled in the vitamin D group, and parathyroid hormone decreased in the vitamin D group compared to the placebo group at week 48 and week 96. There was however no effect on bone formation as measured by procollagen type I N propeptide (PINP), or on bone resorption as measured by C-terminal cross-linking telopeptide of type I collagen (CTX1). Neither PINP nor CTX1 predicted bone loss from baseline to week 96. <br> Conclusions: <br> These findings corroborate the previously reported lack of effect of weekly high dose vitamin D supplementation on bone mass density in the same patients, and suggest that such vitamin D supplementation does not prevent bone loss in persons with MS who are not vitamin D deficient. <br> Trial registration: <br> The trial was registered at ClinicalTrials.gov on April 4 2008, registration number NCT00785473.en_US
dc.descriptionSource at: <a href=https://doi.org/10.1186/s12883-017-0851-0> https://doi.org/10.1186/s12883-017-0851-0 </a>en_US
dc.identifier.citationHolmøy, T., Lindstrøm, J. C., Eriksen, E. F., Steffensen, L. H. & Kampman, M. T. (2017). High dose vitamin D supplementation does not affect biochemical bone markers in multiple sclerosis - a randomized controlled trial. BMC Neurology, 17(67), 1-6. https://doi.org/10.1186/s12883-017-0851-0en_US
dc.identifier.cristinIDFRIDAID 1489445
dc.identifier.doi10.1186/s12883-017-0851-0
dc.identifier.issn1471-2377
dc.identifier.urihttps://hdl.handle.net/10037/12193
dc.language.isoengen_US
dc.publisherBioMed Centralen_US
dc.relation.journalBMC Neurology
dc.relation.urihttps://bmcneurol.biomedcentral.com/articles/10.1186/s12883-017-0851-0
dc.rights.accessRightsopenAccessen_US
dc.subjectVDP::Medisinske Fag: 700::Klinisk medisinske fag: 750::Nevrologi: 752en_US
dc.subjectVDP::Medical disciplines: 700::Clinical medical disciplines: 750::Neurology: 752en_US
dc.titleHigh dose vitamin D supplementation does not affect biochemical bone markers in multiple sclerosis - a randomized controlled trialen_US
dc.typeJournal articleen_US
dc.typeTidsskriftartikkelen_US
dc.typePeer revieweden_US


File(s) in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record